Subgroup Analysis for Chinese Patients Included in the INPULSIS ® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis

ConclusionsNintedanib is clinically efficacious in Chinese patients with IPF with approximately 50% reductions in the rate of decline in FVC, demonstrating slowed disease progression. Similar to the overall INPULSIS® population, nintedanib has a favourable benefit/risk profile in Chinese patients with IPF.ClinicalTrials.gov identifiersNCT01335464, NCT01335477.FundingBoehringer Ingelheim.Plain Language SummaryPlain language summary available for this article.

http://link.springer.com/10.1007/s12325-019-0887-1

Source: Advances in Therapy - February 7, 2019 Category: Drugs & Pharmacology Source Type: research

More News: China Health | Diarrhoea | Drugs & Pharmacology | Gastroenterology | Respiratory Medicine